Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

NCT04395092 is registered in ClinicalTrials.gov with Kiadis Pharma as lead sponsor.

NCT NCT04395092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04395092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Lead sponsor
Kiadis Pharma
Phase
Phase 2
Overall status
Withdrawn
Start date
November 13, 2020
Completion date
November 30, 2023
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), myelodysplastic syndromes (mds)